Despite advances in personalised ocular surface regeneration, the clinical translation of these laboratory advancements requires further optimisation and validation in preclinical studies, including growing the stem cells on a transplantable carrier. Human amniotic membrane has been extensively used in ocular surface regeneration and is the standard carrier for cultivated stem cell transplantation.
We are currently optimising methods for growing iPSC derived corneal cells on human amniotic membrane sheets and aim to test the resultant product in a preclinical model.
Our group is collaborating with international iPSC experts and clinicians to generate clinical-grade iPSC corneal products that can be transplanted into diseases human eyes.
